Parvis Sadjadian

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 185 citations

Medicine, Hematology, Pharmacology +9

Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

Frank Griesinger, Wilfried Eberhardt, Arnd Nusch et al. · Lung Cancer · 2020 · 90 citations · Full text

Medicine, Molecular Medicine, Oncology +13

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations Pretreated With Reversible EGFR Inhibitors

David F. Heigener, Christian Schumann, Martin Sebastian et al. · The Oncologist · 2015 · 87 citations · Full text

Medicine, Oncology, Pharmacology +16

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

Michael Thomas, Santiago Ponce-Aix, Alejandro Navarro et al. · Annals of Oncology · 2018 · 81 citations · Full text

Medicine, Oncology, Pharmacology +15

Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial

Cesare Gridelli, Tudor–Eliade Ciuleanu, Manuel Dómine et al. · British Journal of Cancer · 2020 · 69 citations · Full text

Medicine, Immunology, Oncology +14